Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.
Daniel R. Kuritzkes, MD
Chief, Division of Infectious
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
From Clinical Care Options (CCO): podcast by Drs Rageshri Dhairyawan and Solange L. Baptiste on barriers to HIV care engagement in BIPOC populations globally
Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.
Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen
Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed